Question: Consider the Collaborative Research, Development and Commercialization Agreement between Revolution Medicines, Inc. and Aventis, Inc. (Sanofi); What licenses are granted under this contract?
Relevant contract clauses:
[{"span": [72888, 73394], "answer": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop, Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory.", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}, {"span": [74265, 74896], "answer": "Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive, royalty-free sublicense (which shall only be further sub-licensable (a) to RevMed's Subsidiaries, (b) to the Permitted Contractors or Researchers, and (c) solely with Sanofi's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements.", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}, {"span": [113430, 113730], "answer": "Sanofi shall have rights to use, at no additional cost, any RevMed Study Data in its performance of its obligations and exercise of its rights under the Collaboration except in connection with filing of MAAs for the Indication and Product Treatment Regimen that were the subject of such RevMed Study.", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}, {"span": [156720, 157251], "answer": "To the extent necessary to effect the foregoing in a country other than the United States, each Party grants to the other Party a nonexclusive, irrevocable, perpetual, fully-paid, worldwide license, with the right to grant sublicenses, under the granting Party's interest in Joint Program Technology, for any and all purposes, provided that RevMed's interest therein shall be subject to the other terms and conditions of this Agreement, including the exclusive licenses granted herein (during the Term) and all payment obligations.", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}, {"span": [192363, 192514], "answer": "Upon expiration of this Agreement, the licenses granted to Sanofi under Section 3.1 will become fully paid up, royalty free, perpetual and irrevocable.", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}, {"span": [193470, 194503], "answer": "License Grants.\n\n1. RevMed License to SHP2 Inhibitors. Sanofi shall, effective upon any such termination of this Agreement, and hereby does, grant to RevMed [***], under all [***], and [***], to [***]. Notwithstanding the foregoing, [***] shall not include [***], and [***] shall include [***] (to the extent [***]).\n\n2. RevMed License to Practice Certain Combinations. Sanofi shall, effective upon any such termination of this Agreement, and hereby does, grant to RevMed [***], under [***], and [***] (but excluding [***]). For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(2) do not [***]. 60\n\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020\n\n\n\n\n\n3. Sanofi License to Practice Certain Combinations. [***] RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi [***], under [***], and [***]. For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(3) do not [***]. If Sanofi [***], Sanofi shall so notify RevMed in writing, and [***].", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}, {"span": [207882, 208474], "answer": "All licenses and other rights granted to Sanofi under the RevMed Licensed Technology under this Agreement shall terminate (except as necessary to permit Sanofi to perform its surviving obligations under this Article XII) and all rights thereunder shall revert to RevMed; provided, however, RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi a non- exclusive, worldwide license, with the right to grant sublicenses to contractors and otherwise only with RevMed's prior written consent, under each (1) RevMed Program Invention and (2) [***]. F", "file_path": "cuad/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.txt"}]